Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

ISONIAZID TABLETS

Active
SPE2DP-27-T-0235Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

General Info

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Place of Performance

UNIT 100465 BOX 1, FPO, AP, 96671-4077, USA

Set-Aside

NONE

Documents

1
PDF

AI Contract Breakdown

Uniform Contract Format

Contract not broken down yet

CLEATUS splits the solicitation into Uniform Contract Format (UCF) sections: scope, pricing, deliverables, and evaluation criteria.

Timeline

PhaseSolicitation
Posted

Solicitation

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Get full access to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → MEDICAL SUPPLY CHAIN PHARM FSA
Contacts1 person available
OfficeUSA
Office AddressUSA
Contacts

Full Description

Show more
ISONIAZID TABLETS
ISONIAZID TABLETS<(>,<)> USP, 300 MG,100'S UNIT OF ISSUE "BOTTLE". Store at medical controlled room temperature.
RP001: DLA PACKAGING REQUIREMENTS FOR PROCUREMENT
RA001: THIS DOCUMENT INCORPORATES TECHNICAL AND/OR QUALITY REQUIREMENTS
(IDENTIFIED BY AN 'R' OR AN 'I' NUMBER) SET FORTH IN FULL TEXT IN THE
DLA MASTER LIST OF TECHNICAL AND QUALITY REQUIREMENTS FOUND ON THE WEB
AT:
http://www.dla.mil/HQ/Acquisition/Offers/eProcurement.aspx http://www.dla.mil/HQ/Acquisition/Offers/eProcurement.aspx
FOR SIMPLIFIED ACQUISITIONS, THE REVISION OF THE MASTER IN EFFECT ON THE SOLICITATION ISSUE DATE OR THE AWARD DATE CONTROLS. FOR LARGE ACQUISITIONS, THE REVISION OF THE MASTER IN EFFECT ON THE RFP ISSUE DATE APPLIES UNLESS A SOLICITATION AMENDMENT INCORPORATES A FOLLOW-ON REVISION, IN WHICH CASE THE AMENDMENT DATE CONTROLS.
RQ011: REMOVAL OF GOVERNMENT IDENTIFICATION FROM NON-ACCEPTED SUPPLIES
RD003, COVERED DEFENSE INFORMATION POTENTIALLY APPLIES
MERCURY OR MERCURY CONTAINING COMPOUNDS SHALL
NOT BE INTENTIONALLY ADDED TO<(>,<)> OR COME IN DIRECT
CONTACT WITH<(>,<)> ANY HARDWARE OR SUPPLIES FURNISHED
UNDER THIS CONTRACT. EXCEPTION: FUNCTIONAL MERCURY
USED IN BATTERIES, FLUORESCENT LIGHTS, REQUIRED
INSTRUMENTS; SENSORS OR CONTROLS; WEAPON SYSTEMS;
AND CHEMICAL ANALYSIS REAGENTS SPECIFIED BY NAVSEA.
PORTABLE FLUORESCENT LAMPS AND PORTABLE INSTRUMENTS
CONTAINING MERCURY SHALL BE SHOCK PROOF AND CONTAIN
A SECOND BOUNDARY OF CONTAINMENT OF THE MERCURY OR
MERCURY COMPOUND. (IAW NAVSEA 5100-003D).
This device or drug is regulated by the FDA. Note to Buyers: The contracting official shall send a referral in EBS to the product specialist for confirmation. Please include bidder name and bidder contact information, manufacturer name, manufacturer part number, and item description. RS020: Shelf-life requirement RS001 for a TYPE I (CODE Q) item with a shelf life of 36 months (non-extendable) applies to this item.
Shall be marked IAW the latest edition of Medical Marking Standard No. 1 https://www.dla.mil/Logistics-Operations/Packaging/
MARLEX PHARMACEUTICALS INC 1TAP7 P/N NDC10135080501 GENUS LIFESCIENCES INC 7BH52 P/N NDC64950-0217-10
DLA issues this document using the DoD authorized unit of issue, please refer to the following URL to determine the corresponding ANSI X12 unit of issue.
https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fwww.dla.mil%2FPortals%2F104%2FDocuments% 2FDLMS%2FeApplications%2FLogDataAdmin%2FUnitofIssueandPurchaseUnit.xlsx&wdOrigin=BROWSELINK
SPE2DP-27-T-0235
SECTION B
PR: 7018964578 PRLI: 0001 CONT’D
CLIN PR PRLI UI QUANTITY UNIT PRICE TOTAL PRICE.
0001 7018964578 0001 BT 1.000
NSN/MATERIAL:6505001326904
DELIVERY (IN DAYS):0020
DELIVER FOB: DESTINATION
QTY VARIANCE: PLUS 0% MINUS 0%
INSPECTION POINT: DESTINATION
ACCEPTANCE POINT: DESTINATION
PREP FOR DELIVERY:
PKGING DATA-QUP:001
IF MATERIAL IS CONSIDERED HAZARDOUS IAW FED-STD-313,
PACKAGE IN ACCORDANCE WITH TQ REQUIREMENT IP025.
IF THE MATERIAL IS NOT CONSIDERED HAZARDOUS, IN ACCORDANCE WITH
FED-STD-313, THE MATERIAL SHALL BE COMMERCIALLY PACKAGED IN ACCORDANCE
WITH ASTM D3951.
All DLA Master List of Technical and Quality Requirements take precedence over ASTM D3951. Mark and label all packaging and packing in accordance with MIL-STD-129. The Unit of Issue (U/I) and Quantity per Unit Pack (QUP) will be as specified in the contract/purchase order. PALLETIZATION SHALL BE IN ACCORDANCE WITH RP001: DLA PACKAGING REQUIREMENTS FOR PROCUREMENT
PARCEL POST ADDRESS:
N23191
USNS LEWIS AND CLARK T AKE 1
UNIT 100465 BOX 1
FPO AP 96671-4077
US
SHIP BY TRACEABLE MEANS. DO NOT USE PARCEL POST.
FREIGHT SHIPPING ADDRESS:
N23191
USNS LEWIS AND CLARK T AKE 1
DLA VENDORS: USE VSM FOR
US
M/F: (TCN) N231916305S310
RDD: 319
PROJ: HJ5 TP 3
SUPP ADD: Y02 BI SIG: A
FOR GOVERNMENT USE ONLY: (IPD) 15
DIC: A4A DIST: 9B ADV: 2A FC: E5
Need Ship Date:00/00/0000 Original Required Delivery Date:11/05/2026
SPE2DP-27-T-0235
SECTION B
PR: 7018964578 PRLI: 0001 CONT’D

SPE2DP-27-T-0235 NSN/Part Number: 6505-00-132-6904 Quantity: 1 BT Purchase Request: 7018964578QTY: 1 Delivery: 20 days ADO

Similar Contracts

Same NAICS industry code

NAICS: 325412
New
DIBBS
DIBUCAINE OINTMENT
Solicitation # SPE2DP-27-T-0233
Solicitation SPE2DP-27-T-0233, issued by the DLA Troop Support Medical Supply Chain Pharm FSA, is a request for quotations for the procurement of Dibucaine Ointment, USP. The required product is a rectal ointment containing 1 percent dibucaine as the active ingredient, supplied in a collapsible tube with a rectal applicator. Each unit of issue consists of one package containing one ounce or 28 grams. The product must be stored between 15 and 30 degrees Celsius and is intended for external, rectal administration. The procurement specifies a quantity of one package with a required delivery date of November 5, 2026, and a delivery lead time of 20 days after order. The contract mandates strict adherence to quality and packaging standards, including USP standards, MIL-STD-129 for marking, and Medical Marking Standard No. 1. Packaging must comply with DLA Packaging Requirements for Procurement (RP001) and ASTM D3951 for non-hazardous materials, while hazardous materials must follow TQ requirement IP025 and FED-STD-313. Delivery is FOB Destination, with inspection and acceptance also occurring at the destination. Payment and receiving reports must be processed electronically through the Wide Area WorkFlow (WAWF) system. Key regulatory and legal requirements include compliance with the Buy American Act, the Berry Amendment, and DFARS regulations regarding the safeguarding of covered defense information and the prohibition of certain telecommunications equipment. Offerors must be registered in the System for Award Management (SAM) and provide necessary representations and certifications regarding their business size and socioeconomic status. Quotations are to be submitted via the DIBBS portal by November 9, 2026.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

about 16 hours ago

DEADLINE

in 5 days
View Details
NAICS: 325412
New
DIBBS
SODIUM PERBORATE
Solicitation # SPE2DP-27-T-0229
Solicitation SPE2DP-27-T-0229 is a procurement by the Defense Logistics Agency for one 100 gram bottle of Sodium Perborate in powder form, identified by NSN 6505-01-307-3268. The item is a regulated FDA drug or device and is classified as a Type I (Code Q) item with a non-extendable shelf life of 36 months. Strict storage requirements apply, including avoiding high humidity and maintaining temperatures below 32 degrees Celsius (90 degrees Fahrenheit), while keeping the material away from flammable or combustible substances. Delivery is required within 20 days after receipt of order, with a destination FOB and a required delivery date of August 6, 2026, for shipment to the USS Portland LPD 27 via DLA Distribution San Diego. The contract mandates strict adherence to Medical Marking Standard No. 1, which supersedes MIL-STD-129 for material marking. Packaging must comply with DLA Packaging Requirements for Procurement (RP001) and ASTM D3951 for non-hazardous materials, though TQ requirement IP025 and FED-STD-313 apply if the material is deemed hazardous. Inspection and acceptance will occur at the destination per FAR 52.246-2. The procurement incorporates various federal and defense clauses, including the Buy American Act, DFARS cybersecurity reporting requirements, and the DLA Master List of Technical and Quality Requirements. Invoicing and payment must be processed electronically through the Wide Area WorkFlow system.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

about 16 hours ago

DEADLINE

in 5 days
View Details

More opportunities from Department Of Defense → MEDICAL SUPPLY CHAIN PHARM FSA

Same awarding agency

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS